• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012 Product Image

Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012

  • ID: 2366353
  • December 2012
  • 209 pages
  • Global Markets Direct

Central Nervous System (CNS) Tumor – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Central Nervous System (CNS) Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Central Nervous System (CNS) Tumor. Central Nervous System (CNS) Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Central Nervous System (CNS) Tumor.
- READ MORE >

2
List of Tables 6
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Central Nervous System (CNS) Tumor Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Central Nervous System (CNS) Tumor 12
Central Nervous System (CNS) Tumor Therapeutics under Development by Companies 14
Central Nervous System (CNS) Tumor Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 30
Comparative Analysis 30
Mid Clinical Stage Products 31
Comparative Analysis 31
Early Clinical Stage Products 32
Comparative Analysis 32
Discovery and Pre-Clinical Stage Products 33
Comparative Analysis 33
Central Nervous System (CNS) Tumor Therapeutics – Products under Development by Companies 34
Central Nervous System (CNS) Tumor Therapeutics – Products under Investigation by Universities/Institutes 41
Companies Involved in Central Nervous System (CNS) Tumor Therapeutics Development 62
Genzyme Corporation 62
F. Hoffmann-La Roche Ltd. 63
Vical Incorporated 64
United Therapeutics Corporation 65
Amgen Inc. 66
Sanofi-Aventis 67
Eli Lilly and Company 68
Viralytics Ltd. 69
Genentech, Inc. 70
Nektar Therapeutics 71
Antigenics, Inc. 72
Gamida Cell Ltd. 73
YM BioSciences Inc. 74
Light Sciences Oncology, Inc. 75
Histogen, Inc. 76
Novartis AG 77
Astellas Pharma Inc. 78
Chugai Pharmaceutical Co. Ltd 79
Eisai Co., Ltd. 80
Pfizer Inc. 81
Cell Therapeutics, Inc. 82
Enzon Pharmaceuticals, Inc. 83
Exelixis, Inc. 84
Alfacell Corporation 85
GW Pharmaceuticals plc 86
AEterna Zentaris Inc. 87
Lixte Biotechnology Holdings, Inc. 88
Molecular Insight Pharmaceuticals, Inc. 89
Telik, Inc. 90
Cytomedix, Inc. 91
Diamyd Medical AB 92
Threshold Pharmaceuticals, Inc. 93
Natco Pharma Limited 94
Sareum Holdings plc 95
e-Therapeutics plc 96
MabVax Therapeutics, Inc. 97
Antisense Pharma GmbH 98
Colby Pharmaceutical Company 99
Avaris 100
INSYS Therapeutics, Inc. 101
Bionucleon Srl 102
Ambit Biosciences Corporation 103
NovaRx Corporation 104
immatics biotechnologies GmbH 105
Advantagene, Inc. 106
Ascenta Therapeutics, Inc. 107
Hawthorn Pharmaceuticals, Inc. 108
Arno Therapeutics, Inc. 109
Merrimack Pharmaceuticals, Inc. 110
Neotropix, Inc. 111
Burzynski Research Institute, Inc. 112
Stemline Therapeutics, Inc. 113
APEIRON Biologics AG 114
Cellceutix Corporation 115
TVAX Biomedical, LLC 116
to-BBB technologies BV 117
Targepeutics, Inc. 118
Lipopharma 119
Kringle Pharma, Inc. 120
Archer Biosciences, Inc 121
Galaxy Biotech, LLC 122
ipal GmbH 123
PepTx, Inc. 124
Errant Gene Therapeutics, LLC 125
TAU Therapeutics, LLC 126
EirGen Pharma Ltd. 127
CellAct Pharma GmbH 128
Tocagen Inc 129
Central Nervous System (CNS) Tumor – Therapeutics Assessment 130
Assessment by Monotherapy Products 130
Assessment by Combination Products 131
Drug Profiles 132
Antineoplaston A-10 + Antineoplaston AS2-1 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
trabedersen - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
nimotuzumab - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
Theracim + Radiation Therapy - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
Radiation Therapy + Procarbazine + ACNU - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Radiation Therapy + ACNU - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Temozolomide + Etoposide + Trofosfamid - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 150
Procarbazine + Lomustine + Vincristine - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
Filgrastim + Monoclonal Antibody Ch14.18 + Busulfan + Carboplatin + Cyclophosphamide + Etoposide + Isotretinoin + Melphalan + Vincristine Sulfate - Drug Profile 152
Product Description 152
Mechanism of Action 153
R&D Progress 154
Cytoxan + Melphalan + Autologous Stem Cell Transplantation - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
Product Description 157
Mechanism of Action 157
R&D Progress 157
Chimeric Monoclonal Antibody 14.18 - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
Atengenal + Astugenal - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 160
Cisplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
Cyclophosphamide + Prednisone + Gammaglobulin Therapy - Drug Profile 164
Product Description 164
Mechanism of Action 164
R&D Progress 164
APN-311 - Drug Profile 166
Product Description 166
Mechanism of Action 166
R&D Progress 166
carmustine - Drug Profile 168
Product Description 168
Mechanism of Action 168
R&D Progress 168
temozolomide + Radiation Therapy - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
Eir-060 - Drug Profile 170
Product Description 170
Mechanism of Action 170
R&D Progress 170
Central Nervous System (CNS) Tumor Therapeutics – Drug Profile Updates 171
Central Nervous System (CNS) Tumor Therapeutics – Discontinued Products 175
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products 179
Central Nervous System (CNS) Tumor – Product Development Milestones 207
Featured News & Press Releases 207
Sep 28, 2012: Mitsubishi Tanabe Pharma And Kyowa Hakko File Joint Application For Time-window Extension Of Thrombolytic Agents Grtpa And Activacin 207
Apr 27, 2010: Asahi Kasei Pharma Announces Preliminary Results From Phase III Clinical Study Of AT-877 For Acute Cerebral Infarction 207
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 209
Disclaimer 209

List of Tables
Number of Products Under Development for Central Nervous System (CNS) Tumor, H2 2012 12
Products under Development for Central Nervous System (CNS) Tumor – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Development by Companies, H2 2012 (Contd..2) 17
Number of Products under Development by Companies, H2 2012 (Contd..3) 18
Number of Products under Development by Companies, H2 2012 (Contd..4) 19
Number of Products under Development by Companies, H2 2012 (Contd..5) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Development by Companies, H2 2012 (Contd..1) 35
Products under Development by Companies, H2 2012 (Contd..2) 36
Products under Development by Companies, H2 2012 (Contd..3) 37
Products under Development by Companies, H2 2012 (Contd..4) 38
Products under Development by Companies, H2 2012 (Contd..5) 39
Products under Development by Companies, H2 2012 (Contd..6) 40
Products under Investigation by Universities/Institutes, H2 2012 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 61
Genzyme Corporation, H2 2012 62
F. Hoffmann-La Roche Ltd., H2 2012 63
Vical Incorporated, H2 2012 64
United Therapeutics Corporation, H2 2012 65
Amgen Inc., H2 2012 66
Sanofi-Aventis, H2 2012 67
Eli Lilly and Company, H2 2012 68
Viralytics Ltd., H2 2012 69
Genentech, Inc., H2 2012 70
Nektar Therapeutics, H2 2012 71
Antigenics, Inc., H2 2012 72
Gamida Cell Ltd., H2 2012 73
YM BioSciences Inc., H2 2012 74
Light Sciences Oncology, Inc., H2 2012 75
Histogen, Inc., H2 2012 76
Novartis AG, H2 2012 77
Astellas Pharma Inc., H2 2012 78
Chugai Pharmaceutical Co. Ltd, H2 2012 79
Eisai Co., Ltd., H2 2012 80
Pfizer Inc., H2 2012 81
Cell Therapeutics, Inc., H2 2012 82
Enzon Pharmaceuticals, Inc., H2 2012 83
Exelixis, Inc., H2 2012 84
Alfacell Corporation, H2 2012 85
GW Pharmaceuticals plc, H2 2012 86
AEterna Zentaris Inc., H2 2012 87
Lixte Biotechnology Holdings, Inc., H2 2012 88
Molecular Insight Pharmaceuticals, Inc., H2 2012 89
Telik, Inc., H2 2012 90
Cytomedix, Inc., H2 2012 91
Diamyd Medical AB, H2 2012 92
Assessment by Monotherapy Products, H2 2012 130
Assessment by Combination Products, H2 2012 131
Central Nervous System (CNS) Tumor Therapeutics – Drug Profile Updates 171
Central Nervous System (CNS) Tumor Therapeutics – Discontinued Products 175
Central Nervous System (CNS) Tumor Therapeutics – Discontinued Products (Contd..1) 176
Central Nervous System (CNS) Tumor Therapeutics – Discontinued Products (Contd..2) 177
Central Nervous System (CNS) Tumor Therapeutics – Discontinued Products (Contd..3) 178
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products 179
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..1) 180
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..2) 181
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..3) 182
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..4) 183
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..5) 184
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..6) 185
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..7) 186
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..8) 187
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..9) 188
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..10) 189
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..11) 190
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..12) 191
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..13) 192
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..14) 193
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..15) 194
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..16) 195
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..17) 196
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..18) 197
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..19) 198
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..20) 199
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..21) 200
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..22) 201
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..23) 202
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..24) 203
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..25) 204
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..26) 205
Central Nervous System (CNS) Tumor Therapeutics – Dormant Products (Contd..27) 206

List of Figures
Number of Products under Development for Central Nervous System (CNS) Tumor, H2 2012 12
Products under Development for Central Nervous System (CNS) Tumor – Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Discovery and Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 130
Assessment by Combination Products, H2 2012 131

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos